Bosch Healthcare Solutions GmbH
PCR rapid test for 3 important gastroenteritis pathogens for Vivalytic by Bosch now available / World’s first fully automated PCR test for detection of C. difficile, norovirus, and rotavirus at the sampling point
more
Stories about Medizinische Behandlung
canSERV to Accelerate Your Cancer Research - 2 Calls for Service Provision Open
2 DocumentsmoreMedasense Announces a Strategic Agreement With Global Medical Company, Nihon Kohden Corporation
Ramat Gan, Israel (ots/PRNewswire) - Medasense, a global leader in pain monitoring solutions, is proud to announce a strategic partnership with Nihon Kohden for the exclusive distribution of its revolutionary pain monitoring device in Japan. This partnership is intended to transform pain management practices across Japanese healthcare facilities, offering a significant ...
morePress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
One documentmorePress Release: Restless Legs Syndrome: Genetic Discoveries Advance Treatment and Risk Prediction
Researchers at Helmholtz Munich and the Technical University of Munich (TUM) together with international collaborators have conducted the largest genetic investigation of the restless legs syndrome to date. Their findings, ...
moreSoterios Pharma Announces Positive Topline Results from Phase II Study of STS-01 in the Treatment of Mild / Moderate Alopecia Areata
London (ots/PRNewswire) - - Once-daily topical treatment of mild / moderate alopecia areata (AA) with 1% STS-01 met the primary efficacy endpoint of >30% Severity of Alopecia Tool (SALT) score improvement compared to patients receiving placebo ...
more
Press release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
One documentmorecanSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore- 3
canSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore Bosch Healthcare Solutions GmbH
PCR rapid test for Candida auris for Vivalytic by Bosch now available / World’s first fully automated PCR test for detection of the multidrug-resistant fungus at the point of care
Waiblingen (ots) - - Vivalytic test detects Candida auris in under an hour at the point of care, making it the world’s first test suitable for screenings. - Candida auris infection rates are on the rise in Germany and can cause severe infections, for example of the bloodstream (sepsis). - Hospitals can use the new ...
moreHuma and Merck KGaA, Darmstadt, Germany Launch Innovative App to Support Bladder Cancer Patients
London (ots/PRNewswire) - Huma Therapeutics ("Huma"), a leader in global digital health innovation, together with Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the launch of their innovative bladder cancer treatment companion app in the United Kingdom. This collaboration underscores Merck KGaA, Darmstadt, Germany and Huma's ...
moreAsthma in Children: Researchers Envision Novel Drug to Reduce the Risk of the Disease
Asthma in Children: Researchers Envision Novel Drug to Reduce the Risk of the Disease Scientists have reached a milestone in the research of childhood asthma. For the first time, they have clarified how a certain genetic defect in children initially leads to frequent infections and later to asthma. The study, published in the American Journal of Respiratory and ...
more
Bosch Healthcare Solutions GmbH
Bosch and Randox: Strategic partnership brings highly multiplexing PCR to the point of care / BioMEMS technology enables fully automated, simultaneous testing for hundreds of genetic characteristics in just a few minutes
Waiblingen (ots) - - Bosch and Randox Laboratories Ltd. enter partnership for Vivalytic analysis platform to jointly invest around 150 million euros. - First test to feature novel BioMEMS technology will be a highly multiplexing sepsis IVD grade test. Bosch has agreed on a strategic partnership with Randox ...
moreDr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment
moreARTCLINE successfully completes capital increases of EUR 4.4 million
Rostock, Germany (ots) - Today ARTCLINE GmbH announced the successful completion of two further capital increases. In addition to the founders, in particular family offices from Germany participated in the first capital increase of EUR 0.8 million. In addition, a convertible loan from investors was transferred to equity, so that a second capital increase of EUR 3.6 ...
moreFennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Research Triangle Park, N.C. and Uxbridge, England (ots/PRNewswire) - Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI™, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with ...
more- 4
FDX Fluid Dynamix and Fraunhofer IPK to Collaborate with Lonza on Novel Nanoparticle Formulation Technology Platform FDmiX
more Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘
more
Rising Focus on 'Inceptor' as a Type 2 Diabetes Therapeutic Target
moreExtension of Wastewater Treatment Plant at Koehler Paper in Kehl
moreLeipzig Tourismus und Marketing GmbH
5Pioneering Heart Surgery and Medical Congresses in Leipzig
One documentmoreTherapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial
moreWhat Our Genetic Information Tells Us About Type 2 Diabetes Risk and Complications
moreHearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...
more
- 2
OPTIMA cancer project announces the Region Uppsala as new partner
more Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...
moreNew Source of Stem Cells in Injury-Affected Brains of Patients
moreTakeda Pharma Vertrieb GmbH & Co. KG
The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
Zurich (ots/PRNewswire) - - TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six. - The therapeutical indication for TAKHZYRO® has been extended to patients aged 2 years and older.1 - Offers a New Preventative Treatment Option for young HAE patients with ...
moreBehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics
NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
moreBehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics
NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
more
Previous123456Next